このアイテムのアクセス数: 93

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
MD.0000000000027578.pdf419.66 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorMiyata, Manabuen
dc.contributor.authorOoto, Sotaroen
dc.contributor.authorHata, Masayukien
dc.contributor.authorTakahashi, Ayakoen
dc.contributor.authorTsujikawa, Akitakaen
dc.contributor.alternative宮田, 学ja
dc.contributor.alternative大音, 壮太郎ja
dc.contributor.alternative畑, 匡侑ja
dc.contributor.alternative高橋, 綾子ja
dc.contributor.alternative辻川, 明孝ja
dc.date.accessioned2022-01-26T01:34:59Z-
dc.date.available2022-01-26T01:34:59Z-
dc.date.issued2021-10-
dc.identifier.urihttp://hdl.handle.net/2433/267600-
dc.description.abstractRATIONALE: Bilateral diffuse uveal melanocytic proliferation (BDUMP) is an extremely rare retinal exudative disease with physical disorders and no established treatment standard. We describe treatment courses in 3 cases of BDUMP. PATIENTS CONCERNS: Three male patients complained active vision loss. One male patient in his 70s (patient 1) was treated with prednisolone, mesalazine, and ciclosporin for hypoplastic anemia and ulcerous colitis. One male patient in his 60s (patient 2) was on prednisolone therapy for adult Still disease. Another male patient in his 70s (patient 3) was on prednisolone therapy for polymyalgia rheumatica, giant cell arteritis, and pancreatic body tumor. DIAGNOSES: Retinal specialists diagnosed these patients with BDUMP based on characteristic fundus findings of multiple red patches and retinal exudate. INTERVENTIONS: Two patients (patients 1 and 2) with poor response to anti-vascular endothelial growth factor (VEGF) monotherapy and/or triamcinolone acetonide sub-Tenon injection were treated with combined anti-VEGF therapy and photodynamic therapy. One patient (patient 3) was treated with 3 rounds of monthly anti-VEGF monotherapy. OUTCOMES: Retinal exudates were resolved in all patients. No recurrence of retinal exudates was observed for at least 10 months, 2 years, or 4 months after the therapy in patients 1, 2, and 3, respectively. However, best-corrected visual acuity of the right eye was low (20/200) compared with that of the left eye (20/22) in patient 2 despite exudate resolution, due to permanent outer retinal damage secondary to long-term retinal exudate. LESSONS SUBSECTIONS: Combined anti-VEGF therapy and photodynamic therapy may be a feasible therapeutic option for treatment-resistant exudate in patients with BDUMP. Early diagnosis of BDUMP and prompt administration of combination therapy are crucial.en
dc.language.isoeng-
dc.publisherWolters Kluwer Healthen
dc.rightsCopyright © 2021, Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.en
dc.rightsThis is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectanti-vascular endothelial growth factor therapyen
dc.subjectbilateral diffuse uveal melanocytic proliferationen
dc.subjectcombination therapyen
dc.subjectphotodynamic therapyen
dc.titleEfficacy of combined anti-VEGF and photodynamic therapy for bilateral diffuse uveal melanocytic proliferationen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleMedicineen
dc.identifier.volume100-
dc.identifier.issue42-
dc.relation.doi10.1097/MD.0000000000027578-
dc.textversionpublisher-
dc.identifier.artnume27578-
dc.identifier.pmid34678904-
dcterms.accessRightsopen access-
datacite.awardNumber18K09444-
datacite.awardNumber21K09716-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K09444/-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K09716/-
dc.identifier.pissn0025-7974-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName日本学術振興会ja
jpcoar.awardTitle多角的アプローチによる加齢黄斑変性の病態解明と新規治療の検討ja
jpcoar.awardTitle補償光学光干渉断層計を用いた滲出型加齢黄斑変性の病態解明と新規治療に関する研究ja
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons